WHO vaccine-preventable diseases: monitoring system. 2017 global summary

Last updated 06-Sep-2017 (data as of 05-Sep-2017)
Next overall update 2018
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 4'8001 Infant (under 12 months) mortality rate: 192
GDP / capita (US$): 9'1591 Child (under 5 years) mortality rate: 222

Population data in thousands3

  2016  2015  2014  2013  2012  2000  1990  1980 
Total population 899  892  886  880  874  811  729  635 
Births 17  18  18  18  18  20  21  22 
Surviving infants 17  17  18  18  18  20  21  21 
Pop. less than 5 years 87  88  89  90  91  98  100  92 
Pop. less than 15 years 257  256  255  254  252  284  280  249 
Female 15-49 years 225  224  224  225  225  208  184  161 

Number of reported cases

(Click for retrospective incidence data for Fiji)
Diphtheria
ChartChart
 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  32  913 
Mumps
ChartChart
 
Pertussis
ChartChart
  13 
Polio*
ChartChart
 
Rubella
ChartChart
  25 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Fiji)
Vaccine year result method % card seen                                                
BCG 2007  100  EPI   78  99  99  99  99  99*  99*  95 
DTP1 2007  100  EPI   78  95  98  99  99  93 
DTP3 2007  99  EPI   78  93  96  98  98  91  82  68 
DTP4         
IPV1          93 
HepB_BD          95  99  99  99  99* 
HepB3 2007  99  EPI   78  93  94  98  98  91 
Hib3 2007  99  EPI   78  93  94  98  98  91 
JapEnc         
MCV1          95  95  91  96  90  72  32 
MCV2          95  99*  92  98 
MenA         
PCV1          95  98  91  90 
PCV2          93  94  91  89 
PCV3          93  94  92  87 
Pol3 2007  99  EPI   78  93  94  98  98  91  87  55 
Rota1          95  98  91  90 
RotaC          93  94  91  85 
RCV1          95  95  91  96  90 
TT2plus          95  64  51  81 
PAB          46  90  91 
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Fiji)
BCG
  99  99  99  99  99  96  99  95 
DTP1
  99  99  99  99  99  97  98  87 
DTP3
  99  99  99  99  99  90  97  68 
HepB3
  99  99  99  99  99  98 
HepB_BD
  90  90  90  90  90 
Hib3
  99  99  99  99  99  98 
IPV1
  99 
MCV1
  94  94  94  94  94  81  84  32 
MCV2
  94  94  94  94  94 
PCV3
  99  99  99  87 
Pol3
  99  99  99  99  99  91  96  55 
RCV1
  94  94  94  94  94  81 
RotaC
  99  99  99  85 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country 19  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2016 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTwPHibHepB 6, 10, 14 weeks; Yes
HepB_Adult 1st contact; +6, +14 weeks; Yes health care workers, medical and nursing students
HepB_Pediatric birth; Yes
HPV 8-13 years; + 6 months; Yes
Influenza_Adult Yes elderly. Adults with chronic diseases, pregnant women, health care workers and other risk groups
Influenza_Pediatric Yes and children with chronic diseases
IPV 14 weeks; Yes
MR 12 months; 6 years; Yes
OPV 6, 10, 14 weeks; 18 months; Yes
Pneumo_conj 6, 10, 14 weeks; Yes
Rotavirus 6, 14 weeks; Yes
Td 6, 11 years; Yes also given to pregnant women
VitaminA 6, 12 months; Yes

Immunizaton indicators

Indicator Expected answer 2016  2015  2014  2013  2012  2011  2010 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  No  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number     2013-2015  2013-2015    2007-2011  2007-2011 
Nº of districts with microplans that include activities to raise immunization coverage number 19  19  19  19  19  19  19 

System performance

Total Nº districts in country number 19  19  19  19  19  19  20 
Nº districts with DTP3 coverage >=80% number   19  19  19      17 
% of districts with DTP3 coverage >=80% From 0 to 100%   100  100  100      85 
Nº districts with measles (MCV1) coverage >=95% number           10 
% of districts with MCV1 coverage >=95% From 0 to 100%           50 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%   89  100    100  100  90 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR No  Yes  Yes  Yes  Yes    No 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.